Q5161 Denosumab-kyqq (HCPCS) Reimbursement

HCPCS Level II code Q5161 covers the injection of denosumab-kyqq (Aukelso/Bosaya), a 1 mg biosimilar formulation of denosumab used in conditions involving bone resorption. As a coded entry for a biosimilar monoclonal antibody injection, this code matters nationally because biosimilar biologics are increasingly used to manage biologic therapy costs while maintaining clinical outcomes for patients with osteoporosis, cancer-related bone disease, and other indications where denosumab is appropriate.

Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for denosumab-kyqq, expected sites of service (outpatient infusion/injection centers and physician offices), and the role of a specific HCPCS Level II code in claims processing. The publication outlines benchmarking considerations, common billing scenarios, and policy and coverage implications relevant to payers and provider billing teams.

This summary provides national-level context for coding and billing operations, outlines what to expect in payer coverage reviews, and highlights where to look for policy updates affecting biosimilar injections billed under HCPCS Level II code Q5161. Data not available in the input will be indicated where applicable.

Billing Code Overview

HCPCS Level II code Q5161 denotes an injection of denosumab-kyqq (Aukelso/Bosaya), biosimilar, 1 mg. This code represents administration of a biosimilar formulation of denosumab, an injectable monoclonal antibody that targets RANKL and is commonly used in clinical settings for conditions related to bone resorption.

Service type: Injectable biologic therapy
Typical site of service: Outpatient infusion or injection center, clinic, or physician office

Data not available in the input.

Clinical Context

A typical patient is a postmenopausal woman or an adult with osteoporosis, or a patient with bone loss due to metastatic cancer therapy, who receives a subcutaneous injection of the biosimilar denosumab product Q5161 (denosumab-kyqq, aukelso/bosaya) dosed per milligram. The clinical workflow begins with an office visit or infusion center encounter for evaluation of bone health, review of calcium and vitamin D status, and verification of indication (for example osteoporosis with high fracture risk or prevention of skeletal-related events in malignancy). Baseline laboratory testing (serum calcium, renal function) is verified prior to administration. The patient is positioned for a subcutaneous injection, usually in the upper arm, abdomen, or thigh. The licensed clinician or registered nurse documents the product name denosumab-kyqq, lot number, dose administered (converted from milligrams to the appropriate unit), site of injection, and any immediate adverse reactions. Follow-up instructions include monitoring for hypocalcemia, scheduling of subsequent doses per indication, and documentation of payer, consent, and vaccine/medication administration records when required.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the physician professional portion if a split between professional and technical components exists (rare for drug administration).

Taxonomy Code	Specialty	Notes
`207RG0200X`	Endocrinology, Diabetes & Metabolism	Common specialty managing osteoporosis and denosumab therapy.
`2080P0208X`	Orthopedic Surgery	Orthopedists treating fragility fractures and bone health consultation.
`207L00000X`	Internal Medicine	Primary care physicians overseeing osteoporosis management.
`363LA2200X`	Nurse Practitioner	Advanced practice clinicians who perform medication administration and follow-up.
`367500000X`	Registered Nurse	Nurses who prepare and administer subcutaneous injections in office or infusion centers.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`M81.0`	Age-related osteoporosis without current pathological fracture	Primary indication for denosumab therapy to reduce fracture risk.
`M80.08XA`	Age-related osteoporosis with current pathological fracture, multiple sites, initial encounter	Denosumab may be used as part of management after fracture for bone strengthening.
`C79.51`	Metastasis to bone	Denosumab is used to prevent skeletal-related events in patients with bone metastases from solid tumors.
`M84.50XA`	Pathological fracture, site unspecified, initial encounter for fracture	Related to fragility fractures where antiresorptive therapy may be indicated.
`D86.9`	Sarcoidosis, unspecified	Conditions that affect bone metabolism; used here as an infrequent related diagnosis when bone loss occurs in systemic disease.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify route)	Common code used to report the subcutaneous administration of denosumab in an office setting.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Often billed the same day when an E/M service is performed related to initiation or follow-up of denosumab therapy (use modifier as appropriate).
`36415`	Collection of venous blood by venipuncture	Performed for baseline and follow-up labs such as serum calcium and renal function before administration.
`90471`	Immunization administration (not typically for denosumab)	Included here for workflow analogy; not used for denosumab which is reported with injection administration codes like `96372`.
`G0008`	Administration of influenza vaccine (Medicare specific)	Not applicable to denosumab administration; listed only as a payer-specific administrative code contrast in workflow contexts.

OpenPayer

Summary & Overview

HCPCS Q5161: Denosumab-kyqq (Aukelso/Bosaya) Injection, 1 mg